Exclusive: Biggest Pancreatic Cancer Breakthrough In 50 Years, Says Indian Doctor, Co-Author Of Global Clinical Trial

Daraxonrasib belongs to a new class of medicines known as RAS(ON) inhibitors. The drug targets the active form of RAS proteins, which help drive tumour growth and survival.